Compare BLLN & CALX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLLN | CALX |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | United States | United States |
| Employees | 713 | N/A |
| Industry | Medical Specialities | Telecommunications Equipment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.4B |
| IPO Year | N/A | 2009 |
| Metric | BLLN | CALX |
|---|---|---|
| Price | $80.12 | $52.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $129.57 | $74.75 |
| AVG Volume (30 Days) | 318.7K | ★ 682.2K |
| Earning Date | 03-04-2026 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 157.78 |
| EPS | N/A | ★ 0.26 |
| Revenue | N/A | ★ $510,367,000.00 |
| Revenue This Year | $45.89 | $16.40 |
| Revenue Next Year | $30.17 | $13.75 |
| P/E Ratio | ★ N/A | $194.15 |
| Revenue Growth | N/A | ★ 11.24 |
| 52 Week Low | $61.96 | $29.50 |
| 52 Week High | $138.70 | $71.22 |
| Indicator | BLLN | CALX |
|---|---|---|
| Relative Strength Index (RSI) | 54.69 | 53.29 |
| Support Level | $63.98 | $50.02 |
| Resistance Level | $86.01 | $55.89 |
| Average True Range (ATR) | 5.61 | 1.45 |
| MACD | 1.30 | 0.09 |
| Stochastic Oscillator | 75.47 | 60.63 |
BillionToOne Inc is a molecular diagnostics company. It offers a portfolio of ultrasensitive tests covering prenatal genetic testing, cancer therapy selection, and response monitoring, which are based on its Quantitative Counting Templates (QCT) molecular counting platform. The company's product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, a ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test that measures several genomic loci uniquely methylated in cancer to provide insight into dynamic changes in therapy response.
Calix Inc develops, markets and sells its appliance-based platform, cloud and managed services that enable service providers of all types and sizes to innovate and transform their businesses. The company's customers utilize the real-time data and insights from Calix platforms to simplify their business and deliver experiences that excite their subscribers. The resulting growth in subscriber acquisition, loyalty and revenue creates more value for their businesses and communities. The Company's revenue is principally derived in the United States and it also has its presence in Middle East & Africa, Europe, Asia Pacific and other markets.